NCT04002284View on ClinicalTrials.gov

Anlotinib in Metastatic HER2 Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 12, 2018

Primary Completion Date

January 10, 2020

Study Completion Date

March 15, 2020

Conditions
Breast NeoplasmAntineoplastic AgentsAnlotinib
Interventions
DRUG

Anlotinib Hydrochloride

Anlotinib 12mg p.o. d1-14, 21days/cycle

Trial Locations (1)

100021

National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Peng Yuan

UNKNOWN

NCT04002284 - Anlotinib in Metastatic HER2 Negative Breast Cancer | Biotech Hunter | Biotech Hunter